ID   AACT_HUMAN              Reviewed;         423 AA.
AC   P01011; B3KVQ7; Q13703; Q2TU87; Q2TU88; Q59GP9; Q6LBY8; Q6LDT7;
AC   Q6NSC9; Q8N177; Q96DW8; Q9UC47; Q9UNU9;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 2.
DT   10-MAY-2017, entry version 209.
DE   RecName: Full=Alpha-1-antichymotrypsin;
DE            Short=ACT;
DE   AltName: Full=Cell growth-inhibiting gene 24/25 protein;
DE   AltName: Full=Serpin A3;
DE   Contains:
DE     RecName: Full=Alpha-1-antichymotrypsin His-Pro-less;
DE   Flags: Precursor;
GN   Name=SERPINA3; Synonyms=AACT; ORFNames=GIG24, GIG25;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=6606438; DOI=10.1021/bi00291a001;
RA   Chandra T., Stackhouse R., Kidd V.J., Robson K.J.H., Woo S.L.C.;
RT   "Sequence homology between human alpha 1-antichymotrypsin, alpha 1-
RT   antitrypsin, and antithrombin III.";
RL   Biochemistry 22:5055-5061(1983).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS BOCHUM-1 PRO-78 AND
RP   BONN-1 ALA-252.
RX   PubMed=8244391; DOI=10.1006/geno.1993.1396;
RA   Poller W., Faber J.-P., Weidinger S., Tief K., Scholz S., Fischer M.,
RA   Olek K., Kirchgesser M., Heidtmann H.-H.;
RT   "A leucine-to-proline substitution causes a defective alpha 1-
RT   antichymotrypsin allele associated with familial obstructive lung
RT   disease.";
RL   Genomics 17:740-743(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-9.
RA   Kim J.W.;
RT   "Identification of a human cell growth inhibiting gene.";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT THR-9.
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT THR-9.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND
RP   VARIANTS THR-9 AND ARG-267.
RC   TISSUE=Brain, Liver, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-46, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=3257719; DOI=10.1016/0092-8674(88)90462-X;
RA   Abraham C.R., Selkoe D.J., Potter H.;
RT   "Immunochemical identification of the serine protease inhibitor alpha
RT   1-antichymotrypsin in the brain amyloid deposits of Alzheimer's
RT   disease.";
RL   Cell 52:487-501(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 17-423 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Hippocampus;
RX   PubMed=9880565; DOI=10.1074/jbc.274.3.1821;
RA   Hwang S.-R., Steineckert B., Kohn A., Palkovits M., Hook V.Y.H.;
RT   "Molecular studies define the primary structure of alpha1-
RT   antichymotrypsin (ACT) protease inhibitor in Alzheimer's disease
RT   brains. Comparison of act in hippocampus and liver.";
RL   J. Biol. Chem. 274:1821-1827(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 22-86 AND 130-423 (ISOFORM 1).
RA   Rubin H.;
RL   Submitted (OCT-1989) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   PROTEIN SEQUENCE OF 24-34.
RX   PubMed=2787670; DOI=10.1016/0167-4838(89)90139-8;
RA   Lindmark B., Hilja H., Alan R., Eriksson S.;
RT   "The microheterogeneity of desialylated alpha 1-antichymotrypsin: the
RT   occurrence of two amino-terminal isoforms, one lacking a His-Pro
RT   dipeptide.";
RL   Biochim. Biophys. Acta 997:90-95(1989).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 36-45.
RX   PubMed=7521171; DOI=10.1515/bchm3.1994.375.5.335;
RA   Korzus E., Luisetti M., Travis J.;
RT   "Interactions of alpha-1-antichymotrypsin, alpha-1-proteinase
RT   inhibitor, and alpha-2-macroglobulin with the fungal enzyme,
RT   seaprose.";
RL   Biol. Chem. Hoppe-Seyler 375:335-341(1994).
RN   [12]
RP   PROTEIN SEQUENCE OF 41-60.
RX   PubMed=6687683; DOI=10.1016/0006-291X(83)90325-X;
RA   Morii M., Travis J.;
RT   "Structural alterations in alpha 1-antichymotrypsin from normal and
RT   acute phase human plasma.";
RL   Biochem. Biophys. Res. Commun. 111:438-443(1983).
RN   [13]
RP   PROTEIN SEQUENCE OF 48-68 (ISOFORMS 1/2).
RX   PubMed=8647626;
RX   DOI=10.1002/(SICI)1097-0215(19960529)66:5<636::AID-IJC10>3.0.CO;2-2;
RA   Pinczower G.D., Williams R.P.W., Gianello R.D., Robinson H.C.,
RA   Preston B.N., Linnane A.W.;
RT   "Characterisation of the tumour-associated carbohydrate epitope
RT   recognised by monoclonal antibody 4D3.";
RL   Int. J. Cancer 66:636-644(1996).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 87-129 (ISOFORMS 1/2), AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=2404007;
RA   Rubin H., Wang Z., Nickbarg E.B., McLarney S., Naidoo N.,
RA   Schoenberger O.L., Johnson J.L., Cooperman B.S.;
RT   "Cloning, expression, purification, and biological activity of
RT   recombinant native and variant human alpha 1-antichymotrypsins.";
RL   J. Biol. Chem. 265:1199-1207(1990).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 205-423.
RX   PubMed=6547997; DOI=10.1038/311175a0;
RA   Hill R.E., Shaw P.H., Boyd P.A., Baumann H., Hastie N.D.;
RT   "Plasma protease inhibitors in mouse and man: divergence within the
RT   reactive centre regions.";
RL   Nature 311:175-177(1984).
RN   [16]
RP   REACTIVE SITE.
RX   PubMed=6556193;
RA   Morii M., Travis J.;
RT   "Amino acid sequence at the reactive site of human alpha 1-
RT   antichymotrypsin.";
RL   J. Biol. Chem. 258:12749-12752(1983).
RN   [17]
RP   GLYCOSYLATION AT ASN-93 AND ASN-106.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [18]
RP   INTERACTION WITH DNAJC1.
RX   PubMed=14668352; DOI=10.1074/jbc.M310903200;
RA   Kroczynska B., Evangelista C.M., Samant S.S., Elguindi E.C.,
RA   Blond S.Y.;
RT   "The SANT2 domain of the murine tumor cell DnaJ-like protein 1 human
RT   homologue interacts with alpha1-antichymotrypsin and kinetically
RT   interferes with its serpin inhibitory activity.";
RL   J. Biol. Chem. 279:11432-11443(2004).
RN   [19]
RP   REGION RCL.
RX   PubMed=15638460; DOI=10.1007/s00239-004-2640-9;
RA   Horvath A.J., Forsyth S.L., Coughlin P.B.;
RT   "Expression patterns of murine antichymotrypsin-like genes reflect
RT   evolutionary divergence at the Serpina3 locus.";
RL   J. Mol. Evol. 59:488-497(2004).
RN   [20]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [21]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-33; ASN-93; ASN-106;
RP   ASN-127; ASN-186 AND ASN-271.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-93; ASN-106; ASN-127 AND
RP   ASN-271.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 24-423.
RX   PubMed=2016749; DOI=10.1016/0022-2836(91)90704-A;
RA   Baumann U., Huber R., Bode W., Grosse D., Lesjak M., Laurell C.-B.;
RT   "Crystal structure of cleaved human alpha 1-antichymotrypsin at 2.7-A
RT   resolution and its comparison with other serpins.";
RL   J. Mol. Biol. 218:595-606(1991).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370
RP   AND ARG-372.
RX   PubMed=8836107; DOI=10.1038/nsb1096-888;
RA   Lukacs C.M., Zhong J.Q., Plotnick M.I., Rubin H., Cooperman B.S.,
RA   Christianson D.W.;
RT   "Arginine substitutions in the hinge region of antichymotrypsin affect
RT   serpin beta-sheet rearrangement.";
RL   Nat. Struct. Biol. 3:888-893(1996).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 43-423 OF MUTANTS ARG-370;
RP   ARG-372 AND ARG-374.
RX   PubMed=9521649; DOI=10.1021/bi972359e;
RA   Lukacs C.M., Rubin H., Christianson D.W.;
RT   "Engineering an anion-binding cavity in antichymotrypsin modulates the
RT   'spring-loaded' serpin-protease interaction.";
RL   Biochemistry 37:3297-3304(1998).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 26-423.
RX   PubMed=10618372; DOI=10.1073/pnas.97.1.67;
RA   Gooptu B., Hazes B., Chang W.-S.W., Dafforn T.R., Carrell R.W.,
RA   Read R.J., Lomas D.A.;
RT   "Inactive conformation of the serpin alpha(1)-antichymotrypsin
RT   indicates two-stage insertion of the reactive loop: implications for
RT   inhibitory function and conformational disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:67-72(2000).
RN   [28]
RP   VARIANT ISEHARA-1 VAL-401.
RX   PubMed=1618300; DOI=10.1016/0014-5793(92)80590-D;
RA   Tsuda M., Sei Y., Yamamura M., Yamamoto M., Shinohara Y.;
RT   "Detection of a new mutant alpha-1-antichymotrypsin in patients with
RT   occlusive-cerebrovascular disease.";
RL   FEBS Lett. 304:66-68(1992).
RN   [29]
RP   VARIANT BONN-1 ALA-252.
RX   PubMed=1351206; DOI=10.1016/0140-6736(92)91301-N;
RA   Poller W., Faber J.-P., Scholz S., Weindinger S., Bartholome K.,
RA   Olek K., Eriksson S.;
RT   "Mis-sense mutation of alpha 1-antichymotrypsin gene associated with
RT   chronic lung disease.";
RL   Lancet 339:1538-1538(1992).
RN   [30]
RP   VARIANT VAL-401.
RX   PubMed=11289720; DOI=10.1007/s100380170125;
RA   Tachikawa H., Tsuda M., Onoe K., Ueno M., Takagi S., Shinohara Y.;
RT   "Alpha-1-antichymotrypsin gene A1252G variant (ACT Isehara-1) is
RT   associated with a lacunar type of ischemic cerebrovascular disease.";
RL   J. Hum. Genet. 46:45-47(2001).
CC   -!- FUNCTION: Although its physiological function is unclear, it can
CC       inhibit neutrophil cathepsin G and mast cell chymase, both of
CC       which can convert angiotensin-1 to the active angiotensin-2.
CC       {ECO:0000269|PubMed:2404007}.
CC   -!- SUBUNIT: Interacts with DNAJC1. {ECO:0000269|PubMed:14668352}.
CC   -!- INTERACTION:
CC       Q96KC8:DNAJC1; NbExp=3; IntAct=EBI-296557, EBI-296550;
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P01011-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P01011-2; Sequence=VSP_014227, VSP_014228;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P01011-3; Sequence=VSP_014225, VSP_014226;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Plasma. Synthesized in the liver. Like the
CC       related alpha-1-antitrypsin, its concentration increases in the
CC       acute phase of inflammation or infection. Found in the amyloid
CC       plaques from the hippocampus of Alzheimer disease brains.
CC       {ECO:0000269|PubMed:3257719, ECO:0000269|PubMed:9880565}.
CC   -!- DOMAIN: The reactive center loop (RCL) extends out from the body
CC       of the protein and directs binding to the target protease. The
CC       protease cleaves the serpin at the reactive site within the RCL,
CC       establishing a covalent linkage between the carboxyl group of the
CC       serpin reactive site and the serine hydroxyl of the protease. The
CC       resulting inactive serpin-protease complex is highly stable.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000269|PubMed:12754519,
CC       ECO:0000269|PubMed:14760718, ECO:0000269|PubMed:16335952,
CC       ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:23234360}.
CC   -!- MISCELLANEOUS: Alpha-1-antichymotrypsin can bind DNA.
CC   -!- SIMILARITY: Belongs to the serpin family. {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-4 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA51543.1; Type=Frameshift; Positions=101, 106, 111, 117, 123, 129, 421; Evidence={ECO:0000305};
CC       Sequence=AAT08029.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAT08029.1; Type=Frameshift; Positions=4; Evidence={ECO:0000305};
CC       Sequence=BAD92297.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAA48671.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Alpha-1 antichymotrypsin entry;
CC       URL="https://en.wikipedia.org/wiki/Alpha_1-antichymotrypsin";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K01500; AAA51543.1; ALT_FRAME; mRNA.
DR   EMBL; X68733; CAA48671.1; ALT_INIT; Genomic_DNA.
DR   EMBL; X68734; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68735; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68736; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; X68737; CAA48671.1; JOINED; Genomic_DNA.
DR   EMBL; AY513275; AAT08028.1; -; mRNA.
DR   EMBL; AY513276; AAT08029.1; ALT_SEQ; mRNA.
DR   EMBL; AK123091; BAG53869.1; -; mRNA.
DR   EMBL; AB209060; BAD92297.1; ALT_INIT; mRNA.
DR   EMBL; BC003559; AAH03559.3; -; mRNA.
DR   EMBL; BC010530; AAH10530.1; -; mRNA.
DR   EMBL; BC013189; AAH13189.1; -; mRNA.
DR   EMBL; BC034554; AAH34554.1; -; mRNA.
DR   EMBL; BC070265; AAH70265.1; -; mRNA.
DR   EMBL; M18906; AAA51559.1; -; mRNA.
DR   EMBL; AF089747; AAD08810.1; -; mRNA.
DR   EMBL; J05176; AAA51560.1; -; mRNA.
DR   EMBL; X00947; CAA25459.1; -; Genomic_DNA.
DR   CCDS; CCDS32150.1; -. [P01011-1]
DR   PIR; A90475; ITHUC.
DR   PIR; S62374; S62374.
DR   RefSeq; NP_001076.2; NM_001085.4. [P01011-1]
DR   UniGene; Hs.534293; -.
DR   UniGene; Hs.710488; -.
DR   PDB; 1AS4; X-ray; 2.10 A; A=43-383, B=387-423.
DR   PDB; 1QMN; X-ray; 2.27 A; A=26-423.
DR   PDB; 2ACH; X-ray; 2.70 A; A=24-383, B=384-423.
DR   PDB; 3CAA; X-ray; 2.40 A; A=43-383, B=387-423.
DR   PDB; 3DLW; X-ray; 2.70 A; A=25-423.
DR   PDB; 4CAA; X-ray; 2.90 A; A=43-383, B=387-423.
DR   PDBsum; 1AS4; -.
DR   PDBsum; 1QMN; -.
DR   PDBsum; 2ACH; -.
DR   PDBsum; 3CAA; -.
DR   PDBsum; 3DLW; -.
DR   PDBsum; 4CAA; -.
DR   ProteinModelPortal; P01011; -.
DR   SMR; P01011; -.
DR   BioGrid; 106530; 22.
DR   IntAct; P01011; 10.
DR   STRING; 9606.ENSP00000376793; -.
DR   ChEMBL; CHEMBL5960; -.
DR   MEROPS; I04.002; -.
DR   iPTMnet; P01011; -.
DR   PhosphoSitePlus; P01011; -.
DR   UniCarbKB; P01011; -.
DR   BioMuta; SERPINA3; -.
DR   DMDM; 112874; -.
DR   DOSAC-COBS-2DPAGE; P01011; -.
DR   SWISS-2DPAGE; P01011; -.
DR   EPD; P01011; -.
DR   MaxQB; P01011; -.
DR   PaxDb; P01011; -.
DR   PeptideAtlas; P01011; -.
DR   PRIDE; P01011; -.
DR   DNASU; 12; -.
DR   Ensembl; ENST00000393080; ENSP00000376795; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000467132; ENSP00000450540; ENSG00000196136. [P01011-1]
DR   Ensembl; ENST00000556968; ENSP00000452476; ENSG00000196136. [P01011-2]
DR   GeneID; 12; -.
DR   KEGG; hsa:12; -.
DR   UCSC; uc001ydp.4; human. [P01011-1]
DR   CTD; 12; -.
DR   DisGeNET; 12; -.
DR   GeneCards; SERPINA3; -.
DR   H-InvDB; HIX0079611; -.
DR   HGNC; HGNC:16; SERPINA3.
DR   HPA; CAB016647; -.
DR   HPA; HPA000893; -.
DR   HPA; HPA002560; -.
DR   MalaCards; SERPINA3; -.
DR   MIM; 107280; gene.
DR   neXtProt; NX_P01011; -.
DR   OpenTargets; ENSG00000196136; -.
DR   OpenTargets; ENSG00000273259; -.
DR   Orphanet; 93594; Alpha-1-antichymotrypsin deficiency.
DR   PharmGKB; PA35020; -.
DR   eggNOG; KOG2392; Eukaryota.
DR   eggNOG; COG4826; LUCA.
DR   GeneTree; ENSGT00760000118839; -.
DR   HOVERGEN; HBG005957; -.
DR   InParanoid; P01011; -.
DR   KO; K04525; -.
DR   OMA; FLMIIVP; -.
DR   OrthoDB; EOG091G0ION; -.
DR   PhylomeDB; P01011; -.
DR   TreeFam; TF343201; -.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   ChiTaRS; SERPINA3; human.
DR   EvolutionaryTrace; P01011; -.
DR   GeneWiki; Alpha_1-antichymotrypsin; -.
DR   GenomeRNAi; 12; -.
DR   PMAP-CutDB; P01011; -.
DR   PRO; PR:P01011; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000196136; -.
DR   ExpressionAtlas; P01011; baseline and differential.
DR   Genevisible; P01011; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005622; C:intracellular; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; TAS:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; TAS:UniProtKB.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0006954; P:inflammatory response; NAS:UniProtKB.
DR   GO; GO:0030277; P:maintenance of gastrointestinal epithelium; NAS:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; NAS:UniProtKB.
DR   InterPro; IPR023795; Serpin_CS.
DR   InterPro; IPR023796; Serpin_dom.
DR   InterPro; IPR000215; Serpin_fam.
DR   PANTHER; PTHR11461; PTHR11461; 1.
DR   Pfam; PF00079; Serpin; 1.
DR   SMART; SM00093; SERPIN; 1.
DR   SUPFAM; SSF56574; SSF56574; 1.
DR   PROSITE; PS00284; SERPIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein;
KW   Polymorphism; Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:2787670}.
FT   CHAIN        24    423       Alpha-1-antichymotrypsin.
FT                                /FTId=PRO_0000032411.
FT   CHAIN        26    423       Alpha-1-antichymotrypsin His-Pro-less.
FT                                /FTId=PRO_0000032412.
FT   DNA_BIND    235    237
FT   REGION      369    394       RCL.
FT   REGION      381    389       O-glycosylated at one site.
FT   SITE        383    384       Reactive bond.
FT   CARBOHYD     33     33       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD     93     93       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:14760718,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    106    106       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    127    127       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    186    186       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952}.
FT   CARBOHYD    271    271       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218}.
FT   VAR_SEQ      64     95       LVLKAPDKNVIFSPLSISTALAFLSLGAHNTT -> SPRWS
FT                                IRLCLMYLRRAQKHLLPQQSKSPSFLH (in isoform
FT                                3). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014225.
FT   VAR_SEQ      96    423       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014226.
FT   VAR_SEQ     215    216       AK -> ER (in isoform 2).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_014227.
FT   VAR_SEQ     217    423       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_014228.
FT   VARIANT       9      9       A -> T (in dbSNP:rs4934).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_006973.
FT   VARIANT      78     78       L -> P (in Bochum-1; dbSNP:rs1800463).
FT                                {ECO:0000269|PubMed:8244391}.
FT                                /FTId=VAR_006974.
FT   VARIANT     167    167       A -> G.
FT                                /FTId=VAR_006975.
FT   VARIANT     252    252       P -> A (in Bonn-1; dbSNP:rs17473).
FT                                {ECO:0000269|PubMed:1351206,
FT                                ECO:0000269|PubMed:8244391}.
FT                                /FTId=VAR_006976.
FT   VARIANT     267    267       K -> R (in dbSNP:rs17853314).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_037902.
FT   VARIANT     401    401       M -> V (associated with occlusive-
FT                                cerebrovascular disease; Isehara-1).
FT                                {ECO:0000269|PubMed:11289720,
FT                                ECO:0000269|PubMed:1618300}.
FT                                /FTId=VAR_006977.
FT   VARIANT     407    407       D -> G (in dbSNP:rs10956).
FT                                /FTId=VAR_011742.
FT   CONFLICT     55     55       D -> S (in Ref. 12; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT     69     69       P -> L (in Ref. 1; AAA51543).
FT                                {ECO:0000305}.
FT   CONFLICT    101    101       K -> R (in Ref. 5; BAD92297).
FT                                {ECO:0000305}.
FT   CONFLICT    106    106       N -> Y (in Ref. 3; AAT08028).
FT                                {ECO:0000305}.
FT   CONFLICT    198    198       D -> N (in Ref. 3; AAT08029).
FT                                {ECO:0000305}.
FT   CONFLICT    199    199       L -> P (in Ref. 1; AAA51543).
FT                                {ECO:0000305}.
FT   CONFLICT    234    234       S -> N (in Ref. 3; AAT08029).
FT                                {ECO:0000305}.
FT   CONFLICT    339    339       S -> G (in Ref. 3; AAT08028).
FT                                {ECO:0000305}.
FT   CONFLICT    346    346       I -> S (in Ref. 3; AAT08028).
FT                                {ECO:0000305}.
FT   CONFLICT    361    363       AVL -> VVS (in Ref. 1; AAA51543).
FT                                {ECO:0000305}.
FT   HELIX        49     67       {ECO:0000244|PDB:1AS4}.
FT   STRAND       69     71       {ECO:0000244|PDB:1QMN}.
FT   STRAND       73     75       {ECO:0000244|PDB:1AS4}.
FT   HELIX        77     88       {ECO:0000244|PDB:1AS4}.
FT   HELIX        93    102       {ECO:0000244|PDB:1AS4}.
FT   TURN        107    109       {ECO:0000244|PDB:1AS4}.
FT   HELIX       112    126       {ECO:0000244|PDB:1AS4}.
FT   STRAND      130    132       {ECO:0000244|PDB:1QMN}.
FT   STRAND      134    144       {ECO:0000244|PDB:1AS4}.
FT   HELIX       151    161       {ECO:0000244|PDB:1AS4}.
FT   STRAND      164    168       {ECO:0000244|PDB:1AS4}.
FT   HELIX       170    172       {ECO:0000244|PDB:1QMN}.
FT   HELIX       173    187       {ECO:0000244|PDB:1AS4}.
FT   TURN        188    190       {ECO:0000244|PDB:1AS4}.
FT   STRAND      203    219       {ECO:0000244|PDB:1AS4}.
FT   HELIX       223    225       {ECO:0000244|PDB:1AS4}.
FT   STRAND      227    234       {ECO:0000244|PDB:1AS4}.
FT   STRAND      237    256       {ECO:0000244|PDB:1AS4}.
FT   TURN        257    260       {ECO:0000244|PDB:1AS4}.
FT   STRAND      261    279       {ECO:0000244|PDB:1AS4}.
FT   TURN        281    283       {ECO:0000244|PDB:2ACH}.
FT   HELIX       284    289       {ECO:0000244|PDB:1AS4}.
FT   HELIX       293    302       {ECO:0000244|PDB:1AS4}.
FT   STRAND      304    314       {ECO:0000244|PDB:1AS4}.
FT   STRAND      316    323       {ECO:0000244|PDB:1AS4}.
FT   HELIX       325    330       {ECO:0000244|PDB:1AS4}.
FT   HELIX       335    337       {ECO:0000244|PDB:1AS4}.
FT   HELIX       344    347       {ECO:0000244|PDB:1AS4}.
FT   STRAND      348    350       {ECO:0000244|PDB:1AS4}.
FT   STRAND      352    365       {ECO:0000244|PDB:1AS4}.
FT   STRAND      367    382       {ECO:0000244|PDB:1AS4}.
FT   STRAND      391    394       {ECO:0000244|PDB:1AS4}.
FT   STRAND      399    405       {ECO:0000244|PDB:1AS4}.
FT   STRAND      412    418       {ECO:0000244|PDB:1AS4}.
SQ   SEQUENCE   423 AA;  47651 MW;  B002F946C86A8951 CRC64;
     MERMLPLLAL GLLAAGFCPA VLCHPNSPLD EENLTQENQD RGTHVDLGLA SANVDFAFSL
     YKQLVLKAPD KNVIFSPLSI STALAFLSLG AHNTTLTEIL KGLKFNLTET SEAEIHQSFQ
     HLLRTLNQSS DELQLSMGNA MFVKEQLSLL DRFTEDAKRL YGSEAFATDF QDSAAAKKLI
     NDYVKNGTRG KITDLIKDLD SQTMMVLVNY IFFKAKWEMP FDPQDTHQSR FYLSKKKWVM
     VPMMSLHHLT IPYFRDEELS CTVVELKYTG NASALFILPD QDKMEEVEAM LLPETLKRWR
     DSLEFREIGE LYLPKFSISR DYNLNDILLQ LGIEEAFTSK ADLSGITGAR NLAVSQVVHK
     AVLDVFEEGT EASAATAVKI TLLSALVETR TIVRFNRPFL MIIVPTDTQN IFFMSKVTNP
     KQA
//
